Experimental encapsulating peritoneal sclerosis models: Pathogenesis and treatment

Peritoneal Dialysis International

Volumn 28, Issue SUPPL. 5, 2008, Pages

  Park, Sun Hee ^a,b   Kim, Young Lim ^b   Lindholm, Bengt ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Kyungpook National University Hospital   (South Korea)

Author keywords

Animal model; Encapsulating peritoneal sclerosis

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; ADVANCED GLYCATION END PRODUCT; ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN RECEPTOR; ANTISENSE OLIGONUCLEOTIDE; AQUAPORIN; BENAZEPRIL; CANDESARTAN; CHLORHEXIDINE GLUCONATE; CONNECTIVE TISSUE GROWTH FACTOR; DIALYSIS FLUID; ENDOSTATIN; EVEROLIMUS; FIBRIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GLUCOCORTICOID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; HAMMERHEAD RIBOZYME; INTERCELLULAR ADHESION MOLECULE 1; OLMESARTAN; PIRFENIDONE; QUINAPRIL; ROSIGLITAZONE; TIE 1 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN ANTIBODY; VERY LATE ACTIVATION ANTIGEN 5;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG TARGETING; ENCAPSULATING PERITONEAL SCLEROSIS; FIBRIN DEPOSITION; GENE THERAPY; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; INFLAMMATION; MESOTHELIUM CELL; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PERITONEAL DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; UREMIA; ANIMAL; ANIMAL MODEL; MOUSE; PATHOLOGY; PERITONEUM; RAT; SCLEROSIS;

ANIMALS; HUMANS; MICE; MODELS, ANIMAL; PERITONEAL DIALYSIS; PERITONEUM; RATS; RISK FACTORS; SCLEROSIS;

EID: 67149101183     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802805s05     Document Type: Review

References (58)

1. Kawanishi H. Encapsulating peritoneal sclerosis. Nephrology (Carlton) 2005; 10:249-55.
2. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int 2005; 25(Suppl 4):S19-29.
3. Selgas R, Bajo MA, Paiva A, Del Peso G, Diaz C, Aguilera A, et al. Stability of the peritoneal membrane in long-term peritoneal dialysis patients. Adv Ren Replace Ther 1998; 5:168-78.
4. Mackow RC, Argy WP, Winchester JF, Rakowski TA, Fields PA, Rotellar C, et al. Sclerosing encapsulating peritonitis in rats induced by long-term intraperitoneal administration of antiseptics. J Lab Clin Med 1988; 112:363-71.
5. Lo WK, Chan KT, Leung AC, Pang SW, Tse CY. Sclerosing peritonitis complicating continuous ambulatory peritoneal dialysis with the use of chlorhexidine in alcohol. Adv Perit Dial 1990; 6:79-84.
6. Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14-27.
7. Calo L, Fracasso A, Cantaro S, Cozzi E, De Silvestro G, Plebani M, et al. Plasticizers induced mononuclear cells interleukin 1 production: implications with peritoneal sclerosis. Clin Nephrol 1993; 40:57.
8. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-91.
9. Nakamoto H, Imai H, Ishida Y, Yamanouchi Y, Inoue T, Okada H, et al. New animal models for encapsulating peritoneal sclerosis - role of acidic solution. Perit Dial Int 2001; 21(Suppl 3):S349-53.
10. Hirahara I, Kusano E, Yanagiba S, Miyata Y, Ando Y, Muto S, et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006; 26:380-92.
11. Mackow RC, Winchester JF, Argy WP, Andrews PM, Fields PA, Bates S, et al. Sclerosing encapsulating peritonitis in rats: an experimental study with intraperitoneal antiseptics. Contrib Nephrol 1987; 57:213-18.
12. Levine S, Saltzman A. Abdominal cocoon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16:613-16.
13. Junor BJ, Briggs JD, Forwell MA, Dobbie JW, Henderson I. Sclerosing peritonitis - the contribution of chlorhexidine in alcohol. Perit Dial Bull 1985; 5:101-4.
14. Ishii Y, Sawada T, Shimizu A, Tojimbara T, Nakajima I, Fuchinoue S, et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16:1262-6.
15. Sitter T, Toet K, Fricke H, Schiffl H, Held E, Kooistra T. Modulation of procoagulant and fibrinolytic system components of mesothelial cells by inflammatory mediators. Am J Physiol 1996; 271:R1256-63.
16. Honda K, Nitta K, Horita S, Tsukada M, Itabashi M, Nihei H, et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19:169-75.
17. Sherif AM, Yoshida H, Maruyama Y, Yamamoto H, Yokoyama K, Hosoya T, et al. Comparison between the pathology of encapsulating sclerosis and simple sclerosis of the peritoneal membrane in chronic peritoneal dialysis. Ther Apher Dial 2008; 12:33-41.
18. Imai H, Nakamoto H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of adhesion molecules in the progression of peritoneal sclerosis. Adv Perit Dial 2003; 19:180-5.
19. Duwe AK, Vas SI, Weatherhead JW. Effects of the composition of peritoneal dialysis fluid on chemiluminescence, phagocytosis, and bactericidal activity in vitro. Infect Immun 1981; 33:130-5.
20. Shostak A, Pivnik K, Gotloib L. Daily short exposure of cultured mesothelial cells to lactated, high-glucose, low-pH peritoneal dialysis fluid induces a low-profile regenerative steady state. Nephrol Dial Transplant 1996; 11: 608-13.
21. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
22. Abe K, Miyazaki M, Yoshio Y, Nishino T, Furusu A, Harada T, et al. Angiotensin II blockade ameliorates peritoneal fibrosis and angiogenesis in mouse experimental model of peritoneal fibrosis caused by chlorhexidine gluconate [Abstract]. J Am Soc Nephrol 2002; 13:309A.
23. Imai H, Nakamoto H, Fucshima R, Yamanouchi Y, Ishida Y, Suzuki H. Glucocorticoid protects against the development of encapsulating peritoneal sclerosis on peritoneal dialysis. Adv Perit Dial 2002; 18:124-30.
24. Nishino T, Miyazaki M, Abe K, Furusu A, Mishima Y, Harada T, et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003; 64:887-96.
25. Yoshio Y, Miyazaki M, Abe K, Nishino T, Furusu A, Mizuta Y, et al. TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 2004; 66:1677-85.
26. Io H, Hamada C, Ro Y, Ito Y, Hirahara I, Tomino Y. Morphologic changes of peritoneum and expression of VEGF in encapsulated peritoneal sclerosis rat models. Kidney Int 2004; 65:1927-36.
27. Ro Y, Hamada C, Inaba M, Io H, Kaneko K, Tomino Y. Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 2007; 22:2838-48.
28. Tanabe K, Maeshima Y, Ichinose K, Kitayama H, Takazawa Y, Hirokoshi K, et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int 2007; 71: 227-38.
29. Maruyama N, Fukuda N, Okada K, Matsumoto K. [Development of gene therapy for encapsulating peritoneal sclerosis by a chimeric DNA-RNA hammerhead ribozyme targeting TGF-beta1 mRNA]. Nippon Jinzo Gakkai Shi 2007; 49:113-20.
30. Matsuoka T, Maeda Y, Matsuo K, Naiki Y, Tamai Y, Sakaguchi M, et al. Hepatocyte growth factor prevents peritoneal fibrosis in an animal model of encapsulating peritoneal sclerosis. J Nephrol 2008; 21:64-73.
31. Duman S, Bozkurt D, Sipahi S, Sezak M, Özkan S, Ertilav M, et al. Effects of everolimus as an antiproliferative agent on regression of encapsulating peritoneal sclerosis in a rat model. Adv Perit Dial 2008; 24:104-10.
32. Bozkurt D, Taskin H, Sezak M, Bicak S, Sen S, Ok E, et al. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial 2008; 24:32-8.
33. Hewitson TD, Kelynack KJ, Tait MG, Martic M, Jones CL, Margolin SB, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol 2001; 14: 453-60.
34. Shimizu T, Kuroda T, Hata S, Fukagawa M, Margolin SB, Kurokawa K. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney. Kidney Int 1998; 54: 99-109.
35. Nakazato H, Oku H, Yamane S, Tsuruta Y, Suzuki R. A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level. Eur J Pharmacol 2002; 446:177-85.
36. Misra HP, Rabideau C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol Cell Biochem 2000; 204:119-26.
37. Liu HQ, Wei XB, Sun R, Cai YW, Lou HY, Wang JW, et al. Angiotensin II stimulates intercellular adhesion molecule-1 via an AT1 receptor/ nuclear factor-kappa-b pathway in brain microvascular endothelial cells. Life Sci 2006; 78: 1293-8.
38. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Sugaya T, Ruiz-Ortega M, et al. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal 2005; 7:1261-8.
39. Zweers MM, de Waart DR, Smit W, Struijk DG, Krediet RT. Growth factors VEGF and TGF-beta1 in peritoneal dialysis. J Lab Clin Med 1999; 134:124-32.
40. Margetts PJ, Kolb M, Galt T, Hoff CM, Shockley TR, Gauldie J. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol 2001; 12:2029-39.
41. Liekens S, Verbeken E, Vandeputte M, De Clercq E, Neyts J. A novel animal model for hemangiomas: inhibition of hemangioma development by the angiogenesis inhibitor TNP-470. Cancer Res 1999; 59:2376-83.
42. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003; 9:886-99.
43. Mori S, Ueda T, Kuratsu S, Hosono N, Izawa K, Uchida A. Suppression of pulmonary metastasis by angiogenesis inhibitor TNP-470 in murine osteosarcoma. Int J Cancer 1995; 61:148-52.
44. Nakai A, Satoh M, Hirayoshi K, Nagata K. Involvement of the stress protein HSP47 in procollagen processing in the endoplasmic reticulum. J Cell Biol 1992; 117:903-14.
45. Mishima Y, Miyazaki M, Abe K, Ozono Y, Shioshita K, Xia Z, et al. Enhanced expression of heat shock protein 47 in rat model of peritoneal fibrosis. Perit Dial Int 2003; 23:14-22.
46. Hirahara I, Ogawa Y, Kusano E, Asano Y. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 2004; 19:1732-41.
47. Hirahara I, Inoue M, Okuda K, Ando Y, Muto S, Kusano E. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis - a multicentre study in Japan. Nephrol Dial Transplant 2007; 22:560-7.
48. Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162:1937-49.
49. Sang QX. Complex role of matrix metalloproteinases in angiogenesis. Cell Res 1998; 8:171-7.
50. Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Renal fibrosis. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 2002; 160:2001-8.
51. Ha H, Yu MR, Lee HB. High glucose-induced PKC activation mediates TGF-beta 1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 2001; 59:463-70.
52. Liu F, Liu H, Peng Y, Yuan F, Liu Y, Duan S. Inhibition of transforming growth factor beta (TGFbeta1) expression and extracellular matrix secretion in human peritoneal mesothelial cells by pcDU6 vector-mediated TGFbeta1 shRNA and by pcDNA3.1(-)-mediated antisense TGFbeta1 RNA. Adv Perit Dial 2005; 21:41-52.
53. Ohkawa J, Koguma T, Kohda T, Taira K. Ribozymes: from mechanistic studies to applications in vivo. J Biochem 1995; 118:251-8.
54. Yang J, Liu Y. Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 2003; 284:F349-F357.
55. Ogura Y, Hamanoue M, Tanabe G, Mitsue S, Yoshidome S, Nuruki K, et al. Hepatocyte growth factor promotes liver regeneration and protein synthesis after hepatectomy in cirrhotic rats. Hepatogastroenterology 2001; 48:545-9.
56. Dohi M, Hasegawa T, Yamamoto K, Marshall BC. Hepatocyte growth factor attenuates collagen accumulation in a murine model of pulmonary fibrosis. Am J Respir Crit Care Med 2000; 162:2302-7.
57. Matsuo K, Maeda Y, Naiki Y, Matsuoka T, Tamai Y, Yonekawa S, et al. Possible effects of hepatocyte growth factor for the prevention of peritoneal fibrosis. Nephron Exp Nephrol 2005; 99:e87-94.
58. Nakamura S, Niwa T. Pyridoxal phosphate and hepatocyte growth factor prevent dialysate-induced peritoneal damage. J Am Soc Nephrol 2005; 16:144-50.